Sign in Subscribe
Scientists

Tumor-Homing Peptide Blocks Angiogenesis and Has Potential for Diagnostic and Therapeutic Procedures

Strategic Insights

— 1 min read

A recent study published in the journal Molecular Cancer Research has identified a novel tumor-homing peptide that specifically binds to proteolytically processed collagen IV, accumulates in tumors, and blocks angiogenesis. The peptide, known as TLTYTWS, was generated through a combined in vivo and in vitro phage display screen using a recombinant phage-displayed peptide library. This innovative peptide has the potential to be a useful tool for diagnostic and therapeutic procedures in oncology.

Key Takeaways:

  • The study identified a novel tumor-homing peptide, TLTYTWS, that specifically binds to proteolytically processed collagen IV.
  • TLTYTWS accumulates in tumors but not in control organs, indicating its specificity for tumor vasculature.
  • The peptide blocks angiogenesis in an in vivo assay in a concentration-dependent manner.
  • TLTYTWS significantly reduces endothelial differentiation in vitro, further supporting its anti-angiogenic properties.
  • The study suggests that TLTYTWS may be a useful tool for diagnostic and therapeutic procedures in oncology.
  • Researchers at Technical University of Munich (TUM) developed the peptide through a combined in vivo and in vitro phage display screen.
  • The TLTYTWS peptide can be blocked by coinjection of a chemically synthesized cognate peptide, indicating its specificity.

Statistics:

  • 1078-1085: The journal page numbers where the study was published.
  • 2009: The year when the study was published.
  • 7: The volume number of the journal where the study was published.
  • 7: The issue number of the journal where the study was published.
  • 15: The number of years since the study's publication (2009 to 2024).

Sources:

  • Mueller J, et al. (2019). Targeting of Tumor Blood Vessels: A Phage-Displayed Tumor-Homing Peptide Specifically Binds to Matrix Metalloproteinase-2-Processed Collagen IV and Blocks Angiogenesis In vivo. Molecular Cancer Research, 2009;7(7):1078-1085.
  • American Association Cancer Research. Contact Information.

615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

  • Angiogenesis Weekly Editors (2009). Tumor-Homing Peptide Blocks Angiogenesis and Has Potential for Diagnostic and Therapeutic Procedures. Angiogenesis Weekly via NewsRx.com.

Read more